Beneficial effect induced by a beta-adrenoceptor blocker on fetal growth in streptozotocin-diabetic rats

Neonatology

Volumn 71, Issue 3, 1997, Pages 171-180

  Clabaut, M ^a   Stirnemann, B ^a   Bouftila, B ^a   Robert, I ^a  

^a UNIVERSITÉ DE ROUEN   (France)

Author keywords

Diabetes; Fetal growth; Placenta; Rat; Total adrenoceptor blocker

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INSULIN; OXYGEN RADICAL; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD FLOW VELOCITY; CELL MEMBRANE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG MECHANISM; FEMALE; FETOPLACENTAL UNIT; FETUS; FETUS GROWTH; FETUS WEIGHT; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEMODYNAMICS; INSULIN RELEASE; INTRAVENOUS DRUG ADMINISTRATION; LIPID PEROXIDATION; NONHUMAN; PATHOGENESIS; PLACENTA; PLACENTA CIRCULATION; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; SYSTEMIC CIRCULATION; UMBILICAL ARTERY; UTERINE ARTERY; VEIN BLOOD FLOW;

ABORTION, VETERINARY; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD FLOW VELOCITY; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; HEART RATE; INSULIN; ORGAN SIZE; PLACENTA; PREGNANCY; PREGNANCY IN DIABETICS; PROPRANOLOL; PULSE; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2;

EID: 0030888376     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000244413     Document Type: Article

References (45)

1. Kim JN, Runge W, Well U, Lazarow A: Effects of experimental diabetes oil the offspring of the rat fetal growth, birth weight, gestation period and fetus mortality, Diabetes 1960;90:396-404.
2. Golob EK, Risili S, Becker KL, Moore C: Streptozotocin diabetes in pregnant and nonpregnant rats, Metabolism 1970:19:1014-1019.
3. Sylbuski S, Maugham GB: Use of streptozotocin as diabetic agent in pregnant rat, Endocrinology 1971: 89:1537-1540.
4. Pitkin RM, Van Orden DE: Fetal effects of maternal streptozotocin diabetes, Endocrinology 1974:94: 1247-1253.
5. Ericksson U, Andersson A, Efendie S, Elde R, Hellerstrom C: Diabetes in pregnancy: Effects on the foetal and newborn rat with particular regard to body weight, serum insulin concentration and pancreatic contents of insulin, glucagon and somatostatin, Acta Endocrinol 1980: 94:354-363.
6. Foglia VG, Chieri RA, Cattaneo de Peralta Ramos M: Mechanisms of disturbances during pregnancy in the diabetic female rat, Norm Me-tab Res 1970:2:76-80.
7. Prager R, Abramovici A, Liban E, Laron Z: Histological changes in the placenta of streptozotocin-induced diabetic rats, Diabctologia 1970:10: 89-91.
8. Cougnaud A: Contribution à l'étude expérimentale des perturbations fœ-toplacentaires engendrées par le diabète chez la rate gestante; thèse de 3e cycle, Rouen, 1980.
9. Clabaut M, Cougnaud A, Sehruli J-C: Effects of a vasodilatator, niccr-goline, on foetal and placental growth in diabetic gestating rats, J Pharmacol 1982:13:253-263.
10. Fagerberg SE: Control of blood glucose and diabetic vascular disease, Acta Endocrinol Suppl 1980:239: 42-43.
11. Emmrich P, Muller G: The size of chorionic villi in the placenta of diabetes, Zentralbl Allg Pathol 1974: 118:504-509.
12. Jones JP, Fox H: Placental changes in gestational diabetes: An ultra-structural study, Obstet Gynecol 1976:48:274-280.
13. Bjork O, Persson B: Placental morphology in maternal diabetes mclli-tus, Clin Res 1978:26:189-198.
14. Cougnaud A, Clabaut M, Metayer J, Schrub J-C: Comparaison des lesions placentaires chez la femme et la rate diabétique, J Physiol 1982; 78:3A.
15. Schrub J-C, Vuillermet P, Dero J, Metayer J, Clabaut M: Problèmes actuels de la grossesse chez la diabétique, Rev Endocrinol Clin Nutr Métab 1981;22:305-309.
16. Reynolds ML, Young M: The transfer of free alpha amino nitrogen across the placental membrane in the guinea-pig, J Physiol (Lond) 1971:214:583-587.
17. Morishima HO, Ming-Neng Yell PD, Standley-James L: Reduced uterine blood flow and fetal hypoxemia with acute maternal stress: Experimental observation in the pregnant baboon, Am J Obstet Gynecol 1979:134:270-275.
18. Brent R, Franklin JB: Uterine vascular clamping, a new procedure for the study of congenital malformation, Science 1960:132:89-90.
19. Wigglesworth JS: Fetal growth retardation: Animal model for uterine vessel ligation in the pregnant rat, Am J Pathol 1974;77:347-350.
20. Songer PL, Lose ED, Ulbcrg LC: Reduced blood supply to the uterus as a cause for early embryonic death in the mouse, J Exp Zool 1967:165: 337-344.
21. Franklin JB, Brent RL: The effect of uterine vascular clamping on the development of rat embryos three to fourteen days old, J Morphol 1964; 115:273-290.
22. Garris DR: Regional variations in guinea-pig uterine blood flow during pregnancy: Relationships to intrauterine growth of the fetal-placental unit, Teratology 1983:27:101-107.
23. Ericksson UJ, Jansson L: Diabetes in pregnancy: Decreased placental blood flow and disturbed fetal development in the rat, Pediatr Res 1984; 18:735-738.
24. Chartrel NC, Clabaut ME, Bois-marc FA, Schrub J-C: Uteroplacental hemodynamic disturbances in establishment of fetal growth retardation in streptozotocin-induced diabetic rats, Diabetes 1990:39:743-746.
25. Schocken DD, Caron MG, Lefkowitz RJ: The human placenta, A rich source of fl-adrcncrgie receptors: Characterization of the receptors in particulate and solubilized preparations, J Clin Endocrinol Metab 1980:50:1082-1088.
26. Whitsett JA, Johnson CL, Noguchi A, Darovec-Bcckerman C, Costello M: 1-Adrcncrgic receptors and catecholamine-sensitive adenylate cyclase of the human placenta, J Clin Endocrinol Metab 1980:50:27-32.
27. Falkav G, Kovacs L: Characterization of beta-adrenergic receptors in human myometrium and placenta, Acta Physiol Hung 1985:65:491-495.
28. Collin JY: Characterization of β-adrenoceptors in human placenta, Comparison of placental membranes obtained after either labor or caesarean (poster), Coll Pharmacol Dev, Lyon, June 1985.
29. Bril A, Slivjak M, DiMartino MJ, Feuerstein GZ, Lince P, Poyscr RH, Ruffolo RR Jr, Smith EF III: Cardioprotective effects of carvedilol, a novel P-adrcnoccptor antagonist with vasodilating properties, in anaesthetised minipigs: Comparison with propranolol, Cardiovasc Res 1992;26:518-525.
30. Richer C, Giudicelli J-F: Utilisation de la vélocimétrié Doppler en pharmacologic cardiovasculaire chez le rat; in Péronncau P (ed): Vélocimetrié Doppler applications en pharmacologic vasculaire animale et clinique, Paris, Editions INSERM, 1991, pp 229-241.
31. Gosling RG, King DH: Ultrasound angiology; in Marcus AW, Adamson L (eds): Arteries and Veins, Edinburgh, Churchill Livingstone, 1975, pp 61-98.
32. Hugget ASG, Nixon DA: Use of glucose oxydase, peroxvdase and odia-misidine in determination of blood and urinary glucose, Lancet 1975:2: 368-370.
33. Silbert CK, Sawin CK: Double-antibody radioimmunoassay of serum insulin: Effect of use of hormone depleted human scrum, Clin Chem 1975:21:1520-1522.
34. Weiner CP, Herrig J, Wang J, Farley D, Van Orden D, Chestnut D: Chronic measurement, using the Doppler probe of uterine artery, J Reprod Fertil 1986:77:247-256.
35. Davis LD, Temte JV: Effect of propranolol on the transmembrane potential of ventricular muscle and Purkinje fibers of the dog, Circ Res 1968:22:661.
36. Khambatta HJ, Stone JG, Askanazi J, Khan E: Propranolol increases oxygen utilization during hypoxia, Br J Anaesth 1987:59:1171-1176.
37. Vadlamudi RVSV, Rodgers RL, McNeill JH: The effect of chronic alloxan and streptozotocin-induced diabetes on isolated rat heart performance, Can J Physiol Pharmacol 1982:60:902-911.
38. McNeill JH: Endocrine dysfunction and cardiac performance, Can J Physiol 1985:63:1-8.
39. Regan TJ, Lyons MM, Aimed SS, Levinson GE, Oldewurtel MA, Ahmad MR, Haider B: Evidence for cardiomyopathy in familial diabetes mellitus, J Clin Invest 1977:60:885-889.
40. Götzsche O: Decreased myocardium calcium uptake after isoproterenol in strcptozotocin-induced diabetic rats, Lab Invest 1983:48: 156-161.
41. Lager I, Attvall S, Eriksson BM, Van Schenk H, Smith U: Studies on the insulin-antagonistic effect of catecholamines in normal man, Diabc-tologia 1986:29:409-416.
42. Mak IT, Kramer JH, Freedman AM, Tse SYH, Weglicki WB: Oxygen radical-mediated injury of myocytes - Protection by propranolol, J Mol Cell Cardiol 1990:22:687-695.
43. Sugawara H, Tobise K, Minami H, Uekita K, Yoshie H, Onodera S: Diabetes mellitus and reperfusion injury increase the level of active oxygen-induced lipid peroxidation in rat cardiac membranes, J Clin Exp Med (Igaku no Ayumi) 1992; 163:237-238.
44. Sugawara H, Katsuyuki T, Onodera S: Absence of antioxidant effects of nifedipine and diltiazem on myocardial membrane lipid peroxidation in contrast with those of nisoldipine and propranolol, Biochem Pharmacol 1994;47:887-892.
45. Wentzel P, Jansson L, Eriksson UJ: Diabetes in pregnancy: Uterine blood flow and embryonic development in the rat, Pediatr Res 1995: 38:598-606.